Dr. John Cush RheumNow
3 months 3 weeks ago
SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.
At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.
Dr. John Cush RheumNow
3 months 3 weeks ago
Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z
Dr. John Cush RheumNow
3 months 3 weeks ago
TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 3 weeks ago
#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort:
-enriched in Black patients
-poor response to B-cell depletion inc. Obi
-non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab
-High ferritin = flare @RheumNow https://t.co/3uDMigY8i2
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 3 weeks ago
#EULAR2026 Signing off from the conference 🚆. A lot of learning points and things to consider for tomorrow’s practice, caught up with colleagues and formed new collaborations. Thank you @eular_org. Hope you enjoyed our @RheumNow coverage. See you in Berlin 🇩🇪 #EULAR2027 https://t.co/nyaBnHLrxr
Mrinalini Dey DrMiniDey
3 months 3 weeks ago
Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis.
@ElenaNikiUK
@RheumNow #EULAR2026 https://t.co/UmB63QBl7N
Antoni Chan MD (Prof) synovialjoints
3 months 3 weeks ago
Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.
SUA <300 μmol/L at Week 36:
63.8% vs 40.7% (p<0.0001)
A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile
Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
Do probiotics improve disease activity in PsA?
POS0290: no
MEDISPA RCT n=66
Multispecies probiotics not superior to placebo at week 12
#EULAR2026 @RheumNow https://t.co/1byJ1nB4GF
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 3 weeks ago
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype
Results from the Spanish REGISPON-3
POS1352
#EULAR2026 @RheumNow https://t.co/XicguAdXJ1
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
How many patients with IBD have axSpA?
POS1338 #EULAR2026 @RheumNow
⬇️⬇️⬇️ https://t.co/29qkrCnDYz
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU?
Yes! POS 1347
Multicenter randomised open-label trial
N=56
#EULAR2026 @RheumNow https://t.co/kP7ropPkpC
